---
title: "Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292675219.md"
description: "Palvella Therapeutics released a corporate presentation highlighting positive Phase 3 SELVA results for QTORIN™ rapamycin, with FDA rolling review initiated and NDA completion targeted for H2 2026. The company anticipates U.S. launch in H1 2027, targeting over $1bn peak sales. Palvella holds $262M in cash and secured $230M in financing to support development across its pipeline of six rare disease programs."
datetime: "2026-07-14T20:54:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292675219.md)
  - [en](https://longbridge.com/en/news/292675219.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292675219.md)
generator: "portal-rs"
---

# Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash

**Palvella Therapeutics posted a corporate presentation highlighting positive Phase 3 SELVA results, a rolling NDA submission for QTORIN™ rapamycin and plans for a potential 1H 2027 U.S. launch.**

**Key Highlights:**

-   Filed presentation (Exhibit 99.1) summarizes positive Phase 3 SELVA data: mean mLM-IGA +2.13 at Week 24 (p<0.001).
-   Completed pre-NDA meeting; FDA granted rolling review and first NDA module submitted for microcystic LMs; NDA completion on track 2H 2026.
-   Company expects potential FDA approval and U.S. launch for microcystic LMs in 1H 2027, targeting >30k diagnosed U.S. patients and >$1bn peak sales potential.
-   Pipeline breadth: three QTORIN™ programs across six rare diseases anticipated by year-end 2026 with multiple near-term catalysts (Phase 3 start Q4 2026 for cutaneous VMs).
-   Strong financial position: $262M cash as of 3/31/26 and $230M oversubscribed financing in Feb 2026 to support development and potential U.S. launch.

Original SEC Filing: PALVELLA THERAPEUTICS, INC. \[ PVLA \] - 8-K - Jul. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

- [PVLA: Advanced NDA submission and clinical pipeline with $250.6M cash; net loss widened to $21.9M](https://longbridge.com/en/news/294821621.md)
- [Palvella Therapeutics CEO joins Canaccord Genuity Growth Conference fireside chat](https://longbridge.com/en/news/294958978.md)
- [Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands](https://longbridge.com/en/news/296027938.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**